Key points are not available for this paper at this time.
Doses and schedules of oncology drugs are sometimes inadequately characterized before registration trials. The “more is better” paradigm is still used for dose selection, despite the recognition that targeted therapies require alternative approaches to dose optimization.
Shah et al. (Sat,) studied this question.